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Introduction {#sec010}
============

Metal-on-metal bearings have been used since the early years of total hip arthroplasty (THA) development, and are still used today with 2.000 procedures in 2014 in the National Joint Registry alone \[[@pone.0156051.ref001]\]. Early historical prostheses from the 1960\'s 1970\'s and 1980s include the McKee Farrar hip and Ring hip prosthesis \[[@pone.0156051.ref002]\]. They can be considered the first generation of metal-on-metal total hip arthroplasty (MOM-THA). However, a recent long-term follow-up study of first generation MOM-THA reported increased mortality in patients with metal-on-metal bearings in total hip arthroplasty compared to patients with non-metal-on-metal bearings \[[@pone.0156051.ref003]\]. While this is an isolated report, metal-on-metal bearings in total hip arthroplasty are known to produce metallic particles due to wear and corrosion \[[@pone.0156051.ref004]\]. These metallic particles may lead to local and systemic adverse effects (e.g. nephrotoxicity, cardiotoxicity, carcinogenicity, and structural changes in the visual pathways and basal ganglia), which in turn could lead to increased mortality \[[@pone.0156051.ref005], [@pone.0156051.ref006]\]. These reports are in conflict with two recent registry-based studies of modern, second generation MOM-THA which do not report higher mortality associated with metal-on-metal hips \[[@pone.0156051.ref007], [@pone.0156051.ref008]\]. However, there are concerns that registry-based studies in this setting may be subject to residual confounding \[[@pone.0156051.ref009]\].

The purpose of this systematic review and meta-analysis is therefore to determine the overall mortality and morbidity in randomised controlled trials and observational studies for first- and second-generation metal-on-metal bearings compared to non-metal-on-metal bearings after primary total hip arthroplasty in patients with endstage primary and secondary osteoarthritis.

Materials and Methods {#sec011}
=====================

The reporting of this systematic review is in accordance with the PRISMA statement and a protocol has been registered a priori at the Prospero registry (PROSPERO 2014:CRD42014007417) [S1](#pone.0156051.s001){ref-type="supplementary-material"} and [S2](#pone.0156051.s002){ref-type="supplementary-material"} Files.\[[@pone.0156051.ref010]\]. After the PROSPERO protocol was registered, we also performed a systematic review of observational studies evaluating mortality and medical complications (i.e. cancer incidence, kidney failure or cardiomyopathy) for metal-on-metal bearings compared to non-metal-on-metal bearings in patients with total hip arthroplasty. This would allow us to compare the results from randomised controlled trials (RCTs) to the results from observational studies. The population of interest consisted of patients treated with primary total hip arthroplasty due to endstage primary and secondary osteoarthritis of the hip after failed conservative treatment. The intervention group consisted of patients who received metal-on-metal bearings, including total hip resurfacing with metal bearings: MOM THA. The control group consisted of patients with primary total hip arthroplasty with non-metal-on-metal bearings (e.g. metal-on-polyethylene, metal-on-ceramic, ceramic-on-ceramic, ceramic-on-polyethylene): non-MOM THA.

The primary outcome was mortality, expressed as the number of patients who died within the study period. The secondary outcome was morbidity, expressed as the number of surgical and medical complications experienced by the subjects within the study period.

Data Sources and Searches {#sec012}
-------------------------

The search strategy was composed in collaboration with a librarian experienced in the field of total hip arthroplasty, and included studies, abstracts, and trial registry records from the date of their their inception to the end of March 2015. The following databases were searched: PubMed, MEDLINE, EMBASE, Web of Science, Cochrane, CINAHL, Academic Search Premier. The following journal publisher databases were also searched: ScienceDirect and Wiley. References of included articles were screened for relevant studies. Finally, clinical trial registers (clinicaltrails.org; WHO InternationalClinicalTrialsRegistryPlatform; Multi-register; DutchTrialRegistry) were searched to identify any ongoing trials that were completed but not yet published. Contact persons of eligible trial registry records were contacted by e-mail, and at least two reminders were sent in case of no response.

The search strategy for the RCTs consisted of the following components, each defined by a combination of controlled vocabulary and free text terms:

1.  implant type: metal-on-metal, resurfacing and brand names

2.  total hip arthroplasty

3.  randomised controlled trial.

An example Pubmed search is provided in [S3 File](#pone.0156051.s003){ref-type="supplementary-material"}.

Study Selection {#sec013}
---------------

Initially, the literature was screened on title and abstract. This screening was performed by two reviewers (BP and JM) independently. Both reviewers recorded their findings in a pre-designed electronic database. Both databases were then compared and any disagreements were resolved by consensus or by consulting a referee. When the information in the abstract did not suffice, or if any doubt remained, the studies remained eligible.

The fulltext papers of eligible studies were independently evaluated by two reviewers (BP and JM). Both recorded their findings in a pre-designed electronic database. Any disagreements were resolved by consensus or by consulting a referee.

All bibliographic records identified through the electronic searches were collected in an electronic reference database and subjected to the following inclusion and exclusion criteria:

**Inclusion criteria:** 1) primary total hip arthroplasty

2\) comparison of metal-on-metal bearing with non-metal--on-metal bearing

3\) randomised controlled trial or quasi-randomised controlled trial (for RCTs)

4\) follow-up of at least 3 months.

**Exclusion criteria:** 1) only bilateral cases with metal-on-metal and non-metal-on-metal in the same patient (this would not allow us to determine mortality for the groups separately)

2\) no reporting/evaluation of mortality or morbidity.

Data Extraction and Quality Assessment {#sec014}
--------------------------------------

Two reviewers (BP and JM) independently extracted data and appraised the risk of bias from included studies regarding mortality and morbidity, patient demographics, study characteristics, and implant specifications in a pre-defined electronic data sheet. The data sheet was designed during the extraction of trial data on a random sample of eligible studies. Any disagreements were resolved by consensus or by consulting a referee.

Risk of bias was appraised at the level outcome using the CLEAR-NPT checklist and Cochrane risk of bias table \[[@pone.0156051.ref011]\]. The CLEAR-NPT checklist was specifically designed to appraise the methodological quality of non-pharmacological trials and contains items related to the standardization of the intervention, care provider influence, and additional measures to minimize the potential bias from lack of blinding of participants, care providers, and outcome assessors \[[@pone.0156051.ref011]\]. Any disagreements were resolved by consensus or by consulting a referee.

Data Synthesis and Analysis {#sec015}
---------------------------

A random effects model was employed to pool the risk difference of individual studies in order to estimate an overall risk difference and its associated confidence interval. The inverse variance method, which gives more weight to larger studies, was used to pool outcomes for different studies. The overall effects, corresponding to a random effects model, is reported in the forest plots along with its confidence intervals. The sizes of the square boxes on the forest plots are proportional to the total number of patients in the selected studies. An overall test on heterogeneity between studies was performed. To estimate between-study variance, DerSimonian-Laird's method was employed \[[@pone.0156051.ref012]\]. In case moderators are incorporated in the model, the weighted estimation gives an estimate of the weighted least squares relationship between the moderator variables and the true effect. All analyses were performed using Metafor Package R statistics \[[@pone.0156051.ref013]\]. The measure of interest chosen was risk difference (RD) to account for any \"empty cells\" for mortality or morbidity corresponding to a particular study.

Randomised controlled trials of first and second generation MOM THA and observational studies of first generation MOM THA (evolution of prosthesis development) were eligible for meta-analysis. Observational studies of second generation MOM were considered subject to strong selection bias \[[@pone.0156051.ref007]--[@pone.0156051.ref009]\], so they were not eligible for meta-analysis. The amount of heterogeneity was assessed through visual inspection of forest plots and by calculating tau-squared statistics (which is the amount of heterogeneity in the true RDs) and I-squared statistics. The latter estimates how much of the total variability in the effect size estimates is due to heterogeneity among the true effects. In the presence of heterogeneity, and if data allowed, random effects meta-regression on pre-defined factors (study level covariates) was employed. These factors were defined in the PROSPERO protocol: type of metal bearing (resurfacing vs. non-resurfacing), type of non-metal bearing, head size, fixation method (cemented vs. cementless), indication for THA (primary vs. secondary osteoarthritis), methodological items from CLEAR NPT and Cochrane risk of bias Table, duration of follow-up, mean age at operation, gender distribution (% of females and males), and pre-operative health (American Society of Anesthesiologist (ASA) scores).

To assess for publication bias, we constructed a funnel plot for studies reporting the primary outcome. In the case of asymmetry in the funnel plot, or if publication bias was suspected based on the trial registries, a trim-and-fill method and cumulative meta-analysis was used to explore the magnitude and direction of publication bias.

Results {#sec016}
=======

RCTs {#sec017}
----

The literature search yielded 686 hits and 30 studies (38 papers) published between 1975 and 2014 were included, for a total of 1,806 patients with MOM THA and 2,151 patients with non-MOM THA \[[@pone.0156051.ref002], [@pone.0156051.ref014]--[@pone.0156051.ref042]\]. Three studies were not published in peer reviewed journals (1 abstract, 2 trial registry reports) \[[@pone.0156051.ref019], [@pone.0156051.ref021], [@pone.0156051.ref041]\] and 27 studies \[[@pone.0156051.ref002], [@pone.0156051.ref014]--[@pone.0156051.ref018], [@pone.0156051.ref020], [@pone.0156051.ref022]--[@pone.0156051.ref040], [@pone.0156051.ref042]\] were published in 38 papers; 7 studies on the same RCT were published in more than one paper, including1 study that was published in 3 papers. These papers were mostly follow-up reports. For the analyses, we used the paper with the longest follow-up. Details of study selection and flow of the review are shown in [Fig 1](#pone.0156051.g001){ref-type="fig"} and details of included studies are shown in [Table 1](#pone.0156051.t001){ref-type="table"}.

![PRISMA flow chart.](pone.0156051.g001){#pone.0156051.g001}

10.1371/journal.pone.0156051.t001

###### Details of included RCTs.

![](pone.0156051.t001){#pone.0156051.t001g}

  Author          Publication   MoM                              non-MoM                                           followup time
  --------------- ------------- ----- ----- ----- ---- --- ----- --------- ----- ---- --- ------------------------ ---------------
  Zagra           2013          2nd   20    20    0    0   no    40        40    0    0   Polyethylene---Ceramic   0,33
  Grubl           2006          2nd   15    15    0    0   no    13        13    0    0   Ceramic---Ceramic        1
  Schouten        2012          2nd   39    39    0    0   no    42        42    0    0   Ceramic---metal          1
  Jensen          2011          2nd   21    21    0    0   yes   22        22    0    0   Polyethylene---Ceramic   1
  Zijlstra        2011          2nd   25    25    0    0   no    25        25    0    0   Polyethylene---metal     1
  Hanna           2012          2nd   28    28    0    0   no    23        23    0    0   Polyethylene---metal     2
  Weissinger      2011          2nd   42    42    0    .   no    38        38    0    .   Ceramic---Ceramic        2
  Tiusanen        2013          2nd   46    46    0    2   no    46        46    0    1   Polyethylene---metal     2
  Penny           2012          2nd   21    21    0    0   yes   22        22    0    0   Polyethylene---metal     2
  nct00208494                   2nd   196   196   1    .   no    194       194   1    .   Ceramic---metal          2
  Gauthier        2013          2nd   25    25    0    1   no    25        25    2    0   Polyethylene---metal     2
  Malviya         2011          2nd   50    50    1    2   no    50        50    2    2   Polyethylene---metal     4
  Brodner         2003          2nd   50    50    1    1   no    50        50    2    1   Polyethylene---Ceramic   5
  Gustafson       2014          2nd   26    26    0    1   yes   26        26    0    0   Polyethylene---metal     5
  Macdonald       2005          2nd   23    23    1    0   no    18        18    0    0   Polyethylene---metal     5,1
  Wang            2012          2nd   37    37    0    0   yes   40        40    0    0   Ceramic---Ceramic        6
  Engh            2014          2nd   68    68    2    1   no    37        37    2    1   Polyethylene---metal     6,5
  Bjorgul         2013          2nd   123   129   6    8   no    251       268   16   4   mixed                    7
  Zerahn          2011          2nd   74    74    6    .   no    225       225   14   .   mixed                    7,6
  nct01422564                   2nd   12    12    2    .   no    12        12    0    .   Polyethylene---metal     8
  Hailer          2011          2nd   41    41    1    .   no    44        44    4    .   Polyethylene---metal     8
  Howie           2005          2nd   11    11    0    8   yes   13        13    0    2   Polyethylene---metal     10
  Desmarchelier   2013          2nd   111   125   19   3   no    116       125   13   1   Ceramic---Ceramic        10
  Zijlstra        2010          2nd   101   102   30   4   no    97        98    23   2   Polyethylene---metal     10,7
  Pabinger        2003          2nd   31    32    1    1   no    28        29    1    0   Polyethylene---Ceramic   .

The search of the trial registry reports yielded 111 hits, of which 12 were deemed eligible. The contact persons of these 12 trials were approached. Four did not respond, even after at least 2 reminders. Eight did respond, which resulted in the inclusion of 2 trials. One additional trial was already included as a journal version. Five trial registry reports were excluded because the study was not a randomised controlled trial (n = 4) or there was no information available on mortality or morbidity (n = 1).

Observational studies {#sec018}
---------------------

The literature search yielded 288 hits and 9 studies were included, with a total of 78,110 patients with MOM THA and 451,605 patients with non-MOM THA, published between 1996 and 2014 \[[@pone.0156051.ref003], [@pone.0156051.ref007], [@pone.0156051.ref008], [@pone.0156051.ref043]--[@pone.0156051.ref048]\]. Details of study selection and flow of the review are shown in [Fig 1](#pone.0156051.g001){ref-type="fig"} and details of included studies are shown in [Table 2](#pone.0156051.t002){ref-type="table"}.

10.1371/journal.pone.0156051.t002

###### Results from observational studies.

![](pone.0156051.t002){#pone.0156051.t002g}

  Outcome             Study            Resurfacing   MOM generation   IRR                                         CI           FU     n MOM   n non-MOM
  ------------------- ---------------- ------------- ---------------- ------------------------------------------- ------------ ------ ------- -----------
  All cause           Visuri 2010      No            1st              1.05                                        0.95--1.16   17     579     1585
  Mortality                                                                                                                                   
                      Lubbeke 2014     No            2nd              0.90[\*](#t002fn001){ref-type="table-fn"}   0.70--1.20   9,6    883     2458
                      Makela 2014      Mixed         2nd              0.78                                        0.69--0.88   4,6    10728   18235
                      McMinn 2012a     Yes           2nd              0.61[\*](#t002fn001){ref-type="table-fn"}   0.50--0.75   3,6    8352    53409
                      McMinn 2012b     Yes           2nd              0.68[\*](#t002fn001){ref-type="table-fn"}   0.55--0.84   3,6    8352    50529
                      Kendal 2013a     Yes           2nd              0.51[\*](#t002fn001){ref-type="table-fn"}   0.45--0.59   6      7437    22311
                      Kendal 2013b     Yes           2nd              0.55[\*](#t002fn001){ref-type="table-fn"}   0.47--0.65   5      8101    24303
                                                                                                                                               
  Cancer              Visuri 2010      No            1st              1.27                                        0.98--1.63   17     579     1585
  Mortality                                                                                                                                   
                      Makela 2014      Mixed         2nd              0.78                                        0.63--0.97   4,6    10728   18235
                                                                                                                                               
  Cardiac Mortality   Visuri 2010      No            1st              1.07                                        0.93--1.22   17     579     1585
                      Makela 2014      Mixed         2nd              0.79                                        0.64--0.97   4,6    10728   18235
                                                                                                                                               
  Cancer incidence    Visuri 1996      No            1st              1.25                                        0.99--1.58   13,5   698     1831
                      Smith 2012       No            2nd              1.02[\*](#t002fn001){ref-type="table-fn"}   0.93--1.12   3      21264   248995
                      Lamohamed 2013   No            2nd              1.04[\*](#t002fn001){ref-type="table-fn"}   0.70--1.56   3,2    988     9714
                      Makela 2012      Mixed         2nd              0.92                                        0.81--1.05   4      10728   18235
                      Smith 2012       Yes           2nd              0.72[\*](#t002fn001){ref-type="table-fn"}   0.61--0.86   3      19312   248995

\* hazard ratio. a = cemented. b = uncemented. IRR = incidence rate ratio. FU = follow up in years.

Mortality {#sec019}
---------

There were 25 RCTs (31 papers) that reported mortality \[[@pone.0156051.ref014], [@pone.0156051.ref016]--[@pone.0156051.ref027], [@pone.0156051.ref029], [@pone.0156051.ref031]--[@pone.0156051.ref038], [@pone.0156051.ref040]--[@pone.0156051.ref042]\]. These RCTs comprised 1,225 patients with MOM THA (71 mortalities) and 1,486 patients with non-MOM THA (80 mortalities). There were five observational studies that reported mortality: one with first generation MOM THA and four with second generation MOM THA \[[@pone.0156051.ref003], [@pone.0156051.ref007], [@pone.0156051.ref008], [@pone.0156051.ref043], [@pone.0156051.ref048]\].

Meta-analysis of RCTs and first generation MOM observational studies \[[@pone.0156051.ref003]\] showed a difference trend towards higher mortality for MOM THA: RD 0.7%, 95% CI \[0.0%, 2.3%\], I-square equal to 42%. [Fig 2](#pone.0156051.g002){ref-type="fig"} shows the results of three different meta-analyses, including the RD of the MOM vs. non-MOM studies and the 95% CI associated to each individual study. The overall effect for each separate meta-analysis based on a random effects model is shown. This heterogeneity, I-square 42%, was explained by differences in follow-up, as shown in [Fig 2](#pone.0156051.g002){ref-type="fig"}. After correction for follow-up with random effects meta-regression, there was no residual heterogeneity, and I-square was equal to 0%.

![Forest plot showing the risk difference in mortality between MOM THA and non-MOM THA.\
Overall, there is no difference in mortality between MOM THA and non-MOM THA. After 10 years, there is an increased risk of mortality for MOM THA. Besides one observational study \[[@pone.0156051.ref003]\] of first generation MOM all other studies are RCTs. RE model = random effects model.](pone.0156051.g002){#pone.0156051.g002}

When restricted to studies with long term follow-up (10 years or more) \[[@pone.0156051.ref003], [@pone.0156051.ref035], [@pone.0156051.ref036], [@pone.0156051.ref038]\], the RD was 8.5%, 95% CI \[5.8%, 11.2%\]; number needed to treat was 12. This analysis used the unadjusted data from Visuri et al. \[[@pone.0156051.ref003]\] When using adjusted data from Visuri et al \[[@pone.0156051.ref003]\], the RD was equal to 4.4%, 95% CI \[1.4%, 7.4%\]. Further subgroup analyses and meta-regression revealed no evidence for other modifying factors (e.g. resurfacing vs. non-resurfacing MOM). Sensitivity analyses with "leave one out" methodology indicated that the results were not significantly influenced by any single study.

[Table 2](#pone.0156051.t002){ref-type="table"} shows all-cause mortality and cause-specific mortality for first and second generation MOM observational studies. The first generation MOM observational study, which looked at non-resurfacing MOM in patients with primary osteoarthritis, showed a trend towards increased risk of mortality for patients with MOM compared to non-MOM THA \[[@pone.0156051.ref003]\], Incidence Rate Ratio 1.05, which is in line with the long term results from the RCTs. The second generation MOM observational studies showed decreased risk of mortality for patients with MOM compared to non-MOM-THA, Hazard Ratios ranging from 0.51 to 0.90 \[[@pone.0156051.ref007], [@pone.0156051.ref008], [@pone.0156051.ref043], [@pone.0156051.ref048]\]. This is in contrast with the long-term results from RCTs and first generation observational study.

Morbidity: surgical complications {#sec020}
---------------------------------

There were 26 RCTs (30 papers), all of second generation MOM THA, that reported revisions \[[@pone.0156051.ref014]--[@pone.0156051.ref017], [@pone.0156051.ref025]--[@pone.0156051.ref040], [@pone.0156051.ref042], [@pone.0156051.ref049]--[@pone.0156051.ref052]\]. These studies comprised 1,546 MOM THA (49 revisions) and 1,746 non-MOM THA (24 revisions). There were more revisions in MOM THA compared to non-MOM THA: RD 0.8%, 95% CI \[-0.1%, 1.7%\]; I-square 0%; random effects meta-analysis presented in [Fig 3](#pone.0156051.g003){ref-type="fig"}. This effect was stronger for cemented THA, with more revisions in MOM than non-MOM THA: RD 2.7%, 95% CI \[0.1%, 5.3%\]; number needed to treat was 37.

![Forest plot showing the risk difference in revision surgery between MOM and non-MOM THA.\
There is significantly more revision surgery for MOM THA compared to non-MOM THA. RE model = random effects model.](pone.0156051.g003){#pone.0156051.g003}

Regarding revision for aseptic loosening the RD was 0.6%, 95% CI \[-0.3%, 1.4%\], and regarding revision for septic loosening the RD was 0.3%, 95% CI \[-0.3%, 0.9%\].

Sensitivity analyses with "leave one out" methodology indicated that the results were not significantly influenced by any single study.

Morbidity: medical complications {#sec021}
--------------------------------

There were four RCTs, all of second generation MOM THA, that reported medical complications, with maximum follow-up ranging from 2 to 10 years \[[@pone.0156051.ref019], [@pone.0156051.ref035], [@pone.0156051.ref041], [@pone.0156051.ref050]\]. Since there were only three or fewer RCTs that reported on each medical complication (nephrotoxicity, cardiotoxicity, carcinogenicity, and general medical complications \[e.g. venous thrombosis\]) meta-analysis was not considered appropriate. Data from single studies are reported in [Table 3](#pone.0156051.t003){ref-type="table"}.

10.1371/journal.pone.0156051.t003

###### Medical complications for RCTs.

![](pone.0156051.t003){#pone.0156051.t003g}

  Author          Year   MOM                    non-MOM                
  --------------- ------ ----- --- --- --- ---- --------- --- --- --- ----
  NCT00208494            196   2   1   4   35   194       3   3   5   37
  NCT01422564            12    1   .   1   .    12        0   .   0   .
  Desmarchelier   2013   111   .   .   .   2    116       .   .   .   5
  Penny           2013   18    .   .   .   1    15        .   .   .   0

nephro = nephrotoxicity. cardio = cardiotoxicity.

There were four observational studies that reported cancer incidence: one with first generation MOM THA and three with second generation MOM THA, see [Table 2](#pone.0156051.t002){ref-type="table"} \[[@pone.0156051.ref044]--[@pone.0156051.ref047]\]. The first generation MOM observational study showed increased risk of cancer for patients with MOM compared to non-MOM THA \[[@pone.0156051.ref044]\]. The second generation MOM observational studies showed no difference in risk of cancer for patients with MOM compared to non-MOM THA \[[@pone.0156051.ref045]--[@pone.0156051.ref047]\].

Risk of bias {#sec022}
------------

Risk of bias items from the CLEAR-NPT and Cochrane are presented in [Fig 4](#pone.0156051.g004){ref-type="fig"}. All studies suffered from problems with allocation concealment and blinding of patients, care givers, and outcome assessors.

![Risk of bias tables for CLEAR NPT and Cochrane.](pone.0156051.g004){#pone.0156051.g004}

The strong points of all studies were that compliance with the treatment was of course 100%, follow-up was similar for both MOM and non-MOM groups, and the skill/experience of the surgeons was similar for MOM and non-MOM THA (non-resurfacing).

The results from observational studies of second generation MOM THA were different from those of first generation MOM THA and those of the RCTs, suggesting strong confounding by indication for observational studies of second generation MOM THA \[[@pone.0156051.ref009]\].

Publication bias {#sec023}
----------------

The potential influence of publication bias is small, as shown by a nearly symmetrical funnel plot in [Fig 5](#pone.0156051.g005){ref-type="fig"}. Also, the trim-and-fit method and the cumulative meta-analysis showed small potential influence of publication bias that would not influence the results. Furthermore, the results from the non-published RCTs (identified from the trial registries) were similar to those of published studies: RD for mortality in the non-published studies was -0.3%, 95% CI \[-1.8%, 1.1%\], and in the published studies was 0.1%, 95% CI \[-1.3%, 1.5%\].

![Funnel plot of RCTs.\
The red open boxes represent 1 abstract and 2 trial registry reports that have not been published.](pone.0156051.g005){#pone.0156051.g005}

Discussion {#sec024}
==========

Principal findings {#sec025}
------------------

We found that when restricting to studies with long term follow-up (10 years and more), \[[@pone.0156051.ref003], [@pone.0156051.ref035], [@pone.0156051.ref036], [@pone.0156051.ref038]\] there was an increased risk of mortality in patients with MOM THA compared to patients with non-MOM THA: RD 8.5%, 95% CI \[5.8%, 11.2%\]. This finding, compared to a lack of difference between MOM and non-MOM THA patients with less than 10 years' follow-up, might indicate a dose-response association. The longer patients are exposed to MOM THA, the higher the risk of mortality is compared to non-MOM THA. Importantly, sensitivity analyses with meta-regression showed that duration of follow-up was the only effect modifier.

Regarding surgical morbidity, there were more revisions in MOM THA compared to non-MOM THA: RD 0.8%, 95% CI \[-0.1%, 1.7%\], based on 26 RCTs of second generation MOM THA. When restricted to cemented THA, this effect was stronger: RD 2.7%, 95% CI \[0.1%, 5.3%\].

Since data on post-operative medical complications were reported in only a few studies, no valid meta-analysis could be done on differences between the two THA groups. Regarding the observational studies, one first generation MOM study showed an increased risk of cancer for MOM patients compared to non-MOM THA patients\[[@pone.0156051.ref044]\]. The second generation MOM observational studies showed no difference in overall cancer risk. However, risk of soft-tissue sarcoma and basalioma was higher for MOM THA patients \[[@pone.0156051.ref048]\].

The risk of mortality for MOM THA from observational studies of second generation MOM THA was different from those of first generation MOM THA and RCTs between (non)MoM THA, suggesting confounding by indication in studies of second generation MOM THA as previously reported by Kandala et al \[[@pone.0156051.ref009]\].

In a recent review, Hartmann et al demonstrated that metal ion concentrations were persistently elevated after implantation of MOM bearings in whole blood, serum, plasma, erythrocytes and urine, irrespective of patient characteristics and study characteristics \[[@pone.0156051.ref006]\]. Of concern is that the same authors found very high serum cobalt concentrations in several of their included studies---above 50 μg/L, while the detection limit for serum cobalt is typically 0.3 μg/L. They found the highest metal ion concentrations in patients with a stemmed, large-head MOM implant and in patients with hip resurfacing arthroplasty. Our sensitivity analyses did not identify any association between MOM head size (either resurfacing or THA) and mortality or surgical complications. However the number (25) and size (2700 pts) of our included RCTs may have been too small to detect a difference.

Toxic and carcinogenic effects {#sec026}
------------------------------

Devlin et al and Bradberry et al have shown in a systematic review that patients with suspected Prosthetic Hip Associated Cobalt Toxicity (PHACT) had symptoms that fell in three categories: neuro-ocular toxicity, cardiotoxicity and thyroid toxicity \[[@pone.0156051.ref053], [@pone.0156051.ref054]\]. The signs and symptoms developed between 3 and 72 months (median 19 months) after the MOM THA, \[[@pone.0156051.ref053], [@pone.0156051.ref055]\]. The most common treatment of PHACT in literature was removal of the metal-containing prosthesis, which resulted in lowered cobalt concentration and improvement of symptoms \[[@pone.0156051.ref053]--[@pone.0156051.ref055]\]. Of great concern is also the fact that the International Agency for Research on Cancer (IARC) has classified cobalt as group 2B, *Possibly carcinogenic to humans\"* \[[@pone.0156051.ref056]\]. Furthermore, Moulin et al have shown that metal workers exposed to cobalt have an increased mortality rate from lung cancer \[[@pone.0156051.ref057]\].

Although most emphasis in literature is on cobalt toxicity (PHACT), the effects of chronic exposure to elevated chromium or nickel levels should not be dismissed. The International Agency for Research on Cancer (IARC) has classified chromium and nickel as group 1, \"*carcinogenic to humans\"* \[[@pone.0156051.ref056]\]. Chromium(VI) in particular is carcinogenic through direct DNA damage after intra-cellular reduction to chromium(III), mutation, genomic instability, aneuploidy, and cell transformation \[[@pone.0156051.ref056]\]. Exposure to chromium by ingestion or inhalation is associated with increased risk of lung cancer, sinonasal cancer, and stomach cancer \[[@pone.0156051.ref056], [@pone.0156051.ref058]--[@pone.0156051.ref061]\]. The connection between chromium inhalation/ingestion and an increased risk of lung cancer, sinonasal cancer, stomach cancer, and possibly melanoma do not directly extrapolate to increased cancer risk due to increased plasma chromium levels in MOM THA. Briggs et al have shown a strong relationship between whole blood levels of chromium and total chromosomal aberration indices in peripheral lymphocytes of MOM patients. \[[@pone.0156051.ref062]\] Ladon et al have shown an increase of both chromosome translocations and aneuploidy in peripheral blood lymphocytes at 6, 12, and 24 months after MOM-THA \[[@pone.0156051.ref063]\]. Therefore the association of increased chromium plasma levels and increased risk of mortality through cancer warrants further research. The arguments for this association are the carcinogenic effect of chromium through direct DNA-damage \[[@pone.0156051.ref056]\], strong relationship between whole blood levels of chromium and total chromosomal aberration indices in patients with MOM \[[@pone.0156051.ref062], [@pone.0156051.ref063]\], chronically increased chromium plasma levels in patients with MOM \[[@pone.0156051.ref006]\], and increased long-term mortality in MOM patients as shown by the present systematic review. Furthermore, patients with MOM THA are not only exposed to a single metal but to a \"cocktail\" of metal ions including chromium, cobalt, titanium, nickel, and molybdenum, of which at least two are potentially carcinogenic (chromium and nickel) and one is possibly carcinogenic (cobalt) \[[@pone.0156051.ref006], [@pone.0156051.ref056]\].

Strengths and limitations {#sec027}
-------------------------

Our search strategy was thorough and complete. We included studies published between 1975 and 2014. Also, after contacting corresponding persons, we were able to include additional RCTs (both peer-reviewed papers and clinical trial reports) from trial registries such as clinicaltrials.org. In total, we were able to include 47 papers, including several with follow-up of 10 years or more.

For non-resurfacing THA, the surgical procedure is almost identical for MOM and non-MOM THA. Even the implants are identical with respect to the femoral stem and outer shell of the cup. The only difference is the bearing (liner and femoral head) that is inserted during the procedure. Therefore the surgical skill/experience is the same for non-resurfacing MOM and non-MOM THA.

The fact that the results from observational studies of first generation MOM THA concur with those from the RCTs reinforces the conclusion that MOM patients have an increased risk of mortality in the long run compared to non-MOM patients.

We should consider some limitations. Most RCTs had problems with allocation concealment and blinding during follow-up. However, the primary outcome of mortality is an objective outcome measure and is therefore very unlikely to be misclassified due to problems with blinding. Lack of blinding could have resulted in intensified follow-up for patients with MOM THA once the issues with MOM became apparent. However, none of the included studies mentioned differences in follow-up. Also, if we were to assume intensified follow-up (due to public awareness) for patients with MOM, and that this follow-up would be successful in reducing mortality and morbidity, these effects would have led to an underestimation of the observed effect on mortality and surgical morbidity (revisions) in MOM THA. Thus, in this case the increased risk of long term mortality for MOM THA and the increased risk of revision for MOM THA would even be higher. These unlikely effects would thus not change our conclusions.

There was limited data from RCTs on medical complications. Future RCTs and new reports of existing RCTs should therefore report these complications in a systematic way.

Comparison with other studies {#sec028}
-----------------------------

Visuri et al \[[@pone.0156051.ref003], [@pone.0156051.ref044]\] showed increased mortality and increased cancer incidence from MOM THA in an observational study of first generation MOM hip prostheses implanted between 1967 and 1973: the McKee-Farrar. This study is particularly interesting since the McKee-Farrar is part of the evolution of total hip prostheses and was not subject to modern marketing, nor was it labeled a \"sports hip\". The results from Visuri et al \[[@pone.0156051.ref003]\] are in accordance with the results of the RCTs of second generation (modern) MOM THA, therefore reinforcing our conclusion that MOM THA is associated with an increased risk of mortality in the long term.

Kendal et al found increased mortality in non-MOM THA in a registry based study of second generation MOM THA using propensity score matching \[[@pone.0156051.ref007]\]. Their results are in disagreement with the results of our meta-analysis, likely because registry-based studies are subject to residual confounding by indication. Indeed, Kandala et al have shown that confounding by indication is likely for the Kendal study, since one-fifth of the metal-on-metal subjects are predicted to live beyond 100 years of age, making metal-on-metal total hip replacement more beneficial for longevity than any other known treatment \[[@pone.0156051.ref009]\]. This latter finding is highly unlikely, and confounding by indication for the Kendal study is the most likely reason for this predicted longevity.

Mäkela et al found at short-term follow-up no difference in cancer incidence and cause-specific mortality in patients with second generation MOM THA compared to non-MOM THA \[[@pone.0156051.ref048]\]. For the short-term follow-up, their results are in agreement with the results of our meta-analysis.

Conclusions and implications for clinicians and researchers {#sec029}
-----------------------------------------------------------

Studies with follow-up of greater than 10 years seem to suggest an increased risk of mortality in MOM THA compared to non-MOM THA. Additionally there is an increased risk of revision in MOM THA compared to non-MOM THA. In the light of these results, more long-term follow-up of RCTs reporting mortality is paramount. Also, future observational studies should address the dose-response association of person/hip years exposure to MOM THA and/or levels of metal ions to the risk of mortality and other medical complications e.g. cancer incidence, cardiomyopathy and renal failure.

There is currently no case for the use of MOM THA giving the increased risk of long-term mortality and revision without any proven major advantage. Considering the results discussed above, it is prudent to closely follow the patients that have already received a MOM THA, especially in the long-term.
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